16.10.2018, 902 Zeichen

Valneva: Austrian/French biotech company Valneva SE announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. The Company has now commenced the second stage of its Phase 1 study. A first group of study participants is now being re-vaccinated. This re-vaccination will act as an intrinsic human challenge, with the goal of demonstrating that subjects are protected from vaccine- induced viremia early in the VLA1553 clinical development. Wolfgang Bender, MD, PhD, Chief Medical Officer of Valneva commented, “Our Phase 1trial is progressing well and we are excited to commence the re-vaccination stage. We are strongly committed to use our expertise in vector-borne diseases to find a vaccine solution against this continuing public threat.”
Valneva: weekly performance: -1.14%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/10/2018)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S23/04: Johanna Duchek

Bildnachweis

Aktien auf dem Radar:Amag, Polytec Group, Verbund, Kapsch TrafficCom, Semperit, Frequentis, Wienerberger, Mayr-Melnhof, Palfinger, ATX, ATX Prime, ATX TR, FACC, Pierer Mobility, Porr, ATX NTR, Erste Group, EVN, CPI Europe AG, Lenzing, Addiko Bank, Agrana, BKS Bank Stamm, Oberbank AG Stamm, Josef Manner & Comp. AG, RHI Magnesita, Wolford, Österreichische Post, BASF, 3M, Fresenius Medical Care.

---